BofA lowered the firm’s price target on Hims & Hers to $29 from $32 and keeps an Underperform rating on the shares. The firm says 2026 consensus estimates for Hims’ sales and EBITDA margins are too high. 2026 is a “big investment year” for Hims & Hers and current Street expectations for EBITDA margin expansion “seem overly optimistic,” the analyst tells investors in a research note. BofA sees downside risk to 2026 consensus revenue and EBITDA margins and expects negative earnings revisions to take place over the next few months.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- HIMS Stock Falls after BofA Slashes Price Target to a Street-Low of $29
- Hims & Hers again left off Novo partner list, says Citi
- Mixed options sentiment in Hims and Hers Health with shares down 2.47%
- Mixed options sentiment in Hims and Hers Health with shares down 1.17%
- Hims & Hers Health: Softening Online Metrics and Uncertain GLP-1 Trajectory Drive Underperform (Sell) View